ArticleGenes and immunity2026
Structural and functional analysis of the TGF-β mimic, TGM-2: an immunomodulatory helminth protein.
Article in Genes and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The extraordinary prevalence of helminths is attributable to secretion of molecules that manipulate the host immune system, facilitating their survival. Among the secretory products of the murine intestinal helminth Heligmosomoides polygyrus are 10 mimic proteins with functional resemblance to the mammalian immunosuppressive cytokine, TGF-β, but structurally distinct with five Complement Control Protein (CCP) domains, designated TGM-1 to -10. Here we dissect the structure and function of the mimic TGM-2 and its domains. We generated eight protein truncations lacking N- or C-terminal domains, for testing through pulldowns, mass spectrometric analysis and isothermal titration calorimetry, confirming affinity for TGFBR1 (ALK5), TGFBR2, and the co-receptor CD44. We observed that domains 1-3 bind TGFBR1 and TGFBR2, while domains 4 and 5 exhibit stronger binding to the CD44 co-receptor than TGM-1. Additionally, full-length TGM-2 activates the pSMAD pathway in the MFB-F11 fibroblast cell line at concentrations as low as 1 ng/mL and induces the in vitro conversion of naïve murine CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.